Home > Boards > US OTC > Biotechs > Sunshine Biopharma Inc. (SBFM)

There is some question as to what IP

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Gulo Member Profile
 
Followed By 2
Posts 8
Boards Moderated 0
Alias Born 02/10/02
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/9/2021 4:55:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/3/2021 12:37:30 PM
Information Statement - All Other (definitive) (def 14c) Edgar (US Regulatory) - 10/6/2021 6:01:19 AM
Proxy Statement - Other Information (preliminary) (pre 14c) Edgar (US Regulatory) - 9/21/2021 6:02:36 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2021 12:02:42 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 7/29/2021 4:47:38 PM
Sunshine Biopharma reports Q1 results Seeking Alpha - 5/13/2021 8:50:07 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/30/2021 3:24:52 PM
Sunshine gets new patent application notice of allowance for adva-27a in Europe until 2033 Seeking Alpha - 3/11/2021 9:19:08 AM
CLS Holdings, (OTCQB: CLSH) $1.49 million Net Revenue for Feb Highest in Company History InvestorsHub NewsWire - 3/9/2021 6:37:33 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 12:37:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 12:34:31 PM
Sunshine Bio launches COVID-19 treatment mice study Seeking Alpha - 2/10/2021 8:48:46 AM
SUNSHINE BIOPHARMA INITIATES COVID-19 TREATMENT MICE STUDY InvestorsHub NewsWire - 2/10/2021 8:00:00 AM
CLS Holdings, (OTCQB: CLSH) Record January NET Revenue of $1.48 Million Beating Target InvestorsHub NewsWire - 2/9/2021 6:48:48 AM
SUNSHINE BIOPHARMA SIGNS EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF GEORGIA FOR COVID-19 COMPOUNDS InvestorsHub NewsWire - 2/4/2021 8:00:00 AM
SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING InvestorsHub NewsWire - 2/2/2021 8:00:00 AM
CLS Holdings, (OTCQB: CLSH) $17 million Sales, 60% Growth & 5 New Products InvestorsHub NewsWire - 2/2/2021 6:52:54 AM
SUNSHINE BIOPHARMA COMPLETES APPLICATION TO UPLIST TO OTCQB InvestorsHub NewsWire - 1/27/2021 8:20:00 AM
Epazz, Inc. (OTC Pink: EPAZ) Capitalizes on Blockchain through StreamPay App InvestorsHub NewsWire - 1/26/2021 7:00:00 AM
SUNSHINE BIOPHARMA'S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST THE NEW VARIANT IDENTIFIED IN THE UK InvestorsHub NewsWire - 12/22/2020 8:00:00 AM
SUNSHINE BIOPHARMA ORDERS A NEW BATCH OF Adva-27a FOR TESTING ON TOPII AMPLIFIED CANCERS InvestorsHub NewsWire - 12/8/2020 8:00:00 AM
Gulo   Monday, 03/04/13 03:30:01 PM
Re: jape1 post# 3207
Post # of 102546 
There is some question as to what IP Sunshine actually has.

PCT/FR2003/002330 (= CA 2492940, WO2004/014928) fell apart and has been abandoned. It is no longer Sunshine Biopharma's IP.

Canadian IPO: dead application status: http://patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2492940/financial_transactions.html?type=
USPTO: Abandoned -- Failure to Respond to an Office Action 07-02-2009
EPO: Application deemed to be withdrawn 01.07.2011
https://register.epo.org/espacenet/regviewer?AP=03758183&CY=EP&LG=en&DB=REG

The now invalid patent was apparently originally licensed to Perigene Company, which sublicensed to Protokinetix. Both Protokinetix and Sunshine still seem to claim it as their IP.

Advanomics may still own WO2007/125194 (= PCT/FR2007/000697), but Sirona Biochem (V.SBM) owns the rest of the CF2 -O replacement (carbohydrate) portfolio from INSA and TFChem. They purchased TFChem a couple years ago. The original talent that developed this chemistry is at TFChem.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences